

ORIGINAL ARTICLE

Mutsuo Takahashi · Yoshinobu Hoshii
Hiroo Kawano · Toshikazu Gondo · Tokuhiko Ishihara
Takashi Isobe

Ultrastructural evidence for colocalization of κ light chain- and β_2 -microglobulin-derived amyloids using double labelling immunogold electron microscopy

Received: 16 October 1995 / Accepted: 31 July 1996

Abstract In systemic amyloidosis, it is essential to decide what type of amyloid protein is deposited in tissues before the therapy can be selected and the prognosis assessed in each patient. We examined tissues affected by amyloid deposition from a patient with multiple myeloma by immunohistochemistry and double labelling immunogold electron microscopy and demonstrated colocalization of κ light chain- and β_2 -microglobulin-derived amyloids in the same tissue. β_2 -Microglobulin-derived amyloid had ultrastructurally characteristic features that distinguished it from κ light chain-derived amyloid. This is the first report of the colocalization of two different amyloids by immunoelectron microscopy.

Key words Systemic amyloidosis · κ Light chain-derived amyloid · β_2 -Microglobulin-derived amyloid · Colocalization · Immunogold electron microscopy

Introduction

Amyloidosis is a disorder of protein metabolism characterized by deposition of amyloid fibrils in various tissues and organs. To date, 15 types of amyloid proteins have been identified in humans [12, 25]. Amyloid proteins derived from serum amyloid A (AA), immunoglobulin light chains (AL: A κ , A λ), transthyretin (ATTR), and β_2 -microglobulin (A β_2 -M) are major constituents in sys-

temic amyloidosis. Despite the close histological resemblance of all amyloid deposits, their pathogenesis appears to differ. In general, a single type of amyloid protein is deposited in any individual with systemic amyloidosis, although the coexistence of two or more different types of amyloid proteins has been reported following immunohistochemical investigations [3, 7, 11, 15, 24].

Only one case of amyloidosis showing the coexistence of two different types of amyloid fibrils has been reported in the literature, and both immunohistochemistry and conventional electron microscopy had been used in the study [7]. Whether the coexistence of different amyloid proteins in a single case is merely a phenomenon of trapped serum proteins within amyloid deposits or whether it represents a coincidental deposition of different amyloid proteins is not clear.

In the present study we identified the colocalization of A κ and A β_2 M amyloid fibrils in systemic amyloidosis using the double labelling technique of immunogold electron microscopy.

Materials and methods

The patient, a 62-year-old man, presented with proteinuria at the age of 50 years in 1981, with a clinical diagnosis of hypertensive nephropathy. His renal function steadily deteriorated, and haemodialysis using cuprophane membrane dialyser was conducted in 1987. The cause of renal failure was not confirmed because no renal biopsy was performed during the disease. At that time severe anaemia continued and laboratory data revealed a monoclonal κ light chain spike in serum and urine. Bone marrow aspiration disclosed a diffuse infiltrate of plasma cells comprising 29.6% of the total cell count. Some of these plasma cells had an immature appearance and had two or three nuclei, supporting the diagnosis of multiple myeloma. In 1990, multiple nodules ranging from 3 to 20 mm in greatest dimension appeared in the shoulders and wrists, and in 1992 in the upper eyelids, ear lobes, and tongue. In 1990, a biopsy specimen from the right shoulder disclosed eosinophilic amorphous deposits in the interstitium. In preparations stained with alkaline Congo red [22], the deposits showed birefringence and dichroism under polarized light, indicating that the deposits were amyloid. On immunohistochemical examination (described in detail below), the amyloid reacted with both anti-human amyloid- κ (A κ) and anti-human β_2 -microglobulin (β_2 -M) antisera. VMP (vindesine, melphalan, prednisolone) chemotherapy for mul-

M. Takahashi (✉)
Department of Clinical Laboratory Science,
Yamaguchi University School of Medicine, 1144 Kogushi,
Ube, Yamaguchi, 755 Japan
Tel.: (81) 836-22-2220, Fax: (81) 836-22-2219

Y. Hoshii · H. Kawano · T. Gondo · T. Ishihara
First Department of Pathology,
Yamaguchi University School of Medicine, 1144 Kogushi,
Ube, Yamaguchi, 755 Japan

T. Isobe
Department of Internal Medicine,
Kobe University School of Medicine, 7-5-2 Kusunokicho,
Kobe, Hyogo, 650 Japan




Fig. 1a, b Immunohistochemical staining of the tissue from the right shoulder. **a** Amyloid deposits reacted mainly with anti-Aκ antiserum. **b** A serial section shows focal staining with anti-β₂-microglobulin antiserum. LSAB method, haematoxylin counterstain, ×50

multiple myeloma resulted in a partial remission, but the patient died of acute cardiac failure in his home at the age of 62 years. No autopsy was performed.

Biopsy specimens from the right shoulder, right wrist, right eyelid, and rectum were used for further evaluation of the type of amyloid proteins. Paraffin sections were stained with haematoxylin and eosin and with alkaline Congo red. Formalin-fixed, paraffin-embedded sections of tissues from the right shoulder, right wrist, and right eyelid were used for immunohistochemical study. Small fragments from the right shoulder were fixed in a buffered 2.1% glutaraldehyde solution for electron microscopy.

For immunohistochemistry, formalin-fixed, paraffin-embedded sections were prepared according to the labelled streptavidin biotin (LSAB) method [23]. Primary antibodies used in the present study were: monoclonal anti-human amyloid A protein (AA) antibody (1:5000; Dakopatts, Glostrup, Denmark), polyclonal rabbit anti-human Aκ (1:4000) and anti-human Aλ (1:8000) antisera (anti-human Aκ and Aλ antisera were kindly provided by Dr. George G. Glenner, Department of Pathology, University of California, San Diego, School of Medicine, La Jolla, California; Aκ was produced from patient A68, V_κ^{L1} and Aλ from patient A66, V_λ^{II} or V_λ^{IV}; production and specificity of these antisera have been described elsewhere [13]), polyclonal rabbit anti-human transthyretin (TTR) antiserum (1:600; Dakopatts), and polyclonal rabbit anti-human β₂-microglobulin (β₂-M) antiserum

(1:2000; Nordic Immunological Laboratories, Tilburg, The Netherlands). These primary antibodies were incubated overnight at 4°C.

For immunogold electron microscopy glutaraldehyde-fixed tissues were postfixated in 1% osmium tetroxide for 1 h, dehydrated in alcohol, and embedded in Epon 812. Thin sections were stained with uranyl acetate and lead citrate for conventional electron microscopy.

For the immunoelectron microscopic procedure, the blocks were prepared by standard procedures for electron microscopy. Silver grey sections of selected areas were cut and mounted on nickel grids. Before immunocytochemical labelling, thin sections were pretreated for 60 min in a saturated aqueous solution of sodium metaperiodate according to the method of Bendayan and Zolinger [2]. After washing in 0.01 M phosphate-buffered saline (PBS), pH 7.4, the pretreated thin sections were incubated for 30 min in 1% bovine serum albumin in PBS to block nonspecific binding sites. The sections were then transferred onto a drop of polyclonal rabbit anti-Aκ (1:4000) or anti-β₂-M (1:10000) antiserum and incubated for 4 h. After a rapid wash in PBS, the sections were incubated with colloidal gold (10-nm and 20-nm gold particles, respectively)-labelled goat anti-rabbit IgG antisera (1:10; 10-nm gold particles: Janssen Biotech, Olen, Belgium; 20-nm gold particles: EY Laboratories, San Mateo, USA) for 1 h. All incubations were performed at room temperature. After washing in PBS, rinsing in distilled water, and drying, sections were stained with uranyl acetate and lead citrate.




Fig. 2 At a low magnification of conventional electron microscopy, amyloid deposits show a nodular configuration with a rim of electron-dense lamellae. ×2800

The double labelling procedure of immunogold electron microscopy was done according to the method of Bendayan [1]. The tissue sections were mounted on uncoated nickel grids. In this way the tissue sections have two faces exposed. Immunolabelling of one face of the grid was performed as mentioned above with anti-human β 2-M antiserum as the primary antibody and colloidal gold-labelled goat anti-rabbit IgG antiserum (20 nm). The other face of the grid was then labelled with anti-human A κ antiserum as the primary antibody and colloidal gold-labelled goat anti-rabbit IgG antiserum (10 nm). Care was taken not to wet the opposite face during the incubations. The sections were stained on only one face with uranyl acetate and lead citrate. They were examined with Hitachi H-800 and H-7000 electron microscopes. The specificity of immunoelectron microscopic staining was confirmed by replacing the primary antibodies with anti-AA antibody, anti-A λ antiserum or nonimmune goat serum. Sections from AA, A κ , A λ , or A β 2M amyloidosis were used as positive controls.

Results

The tissue from the right shoulder, right wrist, right eyelid, and rectum revealed massive deposits of eosinophilic homogeneous materials in the interstitium or around small vessels. All stained with alkaline Congo red and




Fig. 3 A higher magnification of the nodular area of amyloid deposit shows the presence of two morphologically different fibrils. One has a thin, rigid, straight configuration and the other has a thick, curvilinear or comma-like appearance. $\times 10000$

showed apple green birefringence under polarized light, indicating the presence of amyloid deposition.

Immunohistochemically, amyloid deposits in the right shoulder and right wrist reacted mainly with A κ (Fig. 1a), focally with β 2-M (Fig. 1b) and weakly with A λ , but not at all with AA or TTR antiserum. Amyloid reacted with A κ antiserum tended to be deposited in a nodular configuration, and that reacted with β 2-M antiserum appeared to locate around the A κ amyloid nodules. The tissue from the right eyelid reacted only with A κ antiserum.

Ultrastructurally the deposits consisted of diffusely distributed fine fibrils. Small nodular to patchy accumulations of the fibrils were occasionally observed. In the areas of the nodular accumulations electron-dense fibrils were seen at the rim of the nodules arranged in a lamellar fashion (Fig. 2). At a higher magnification the inner area of the nodules was composed of rigid, straight, nonbranching fibrils, measuring 8–11 nm in diameter and of indeterminate length, indicating ordinary amyloid fibrils reported in AL or AA amyloidosis. At the rim of the nodules there was a different kind of fibril, which measured 12–14 nm in diameter and had a “curvilinear” or comma-like appearance (Fig. 3). In the diffuse area of amyloid deposits, these two thin and thick fibrils seemed to be intermingled with collagen fibres.

In the single labelling preparations of the immunogold technique, the reaction product (10-nm gold particles) to anti-A κ antiserum labelled specifically thin amyloid fibrils (8–11 nm diameter) at the inner area of the nodular deposits. These amyloid fibrils were haphazardly arranged without forming bundles (Fig. 4a). However, 20-nm gold particles to anti- β 2-M antiserum labelled thick amyloid fibrils (12–14 nm diameter) at the rim of the nodules specifically. These tended to form short curved bundles and were arranged in a whorling fashion (Fig. 4b).

The double labelling preparation clearly demonstrated the topographic localization of the different sizes of gold particles on individual amyloid fibrils in the nodular deposits (Fig. 4c). These different sizes of gold particles did not decorate any amyloid fibril together. In the diffuse area of amyloid deposits, different-sized amyloid fibrils were intermingled and the thin amyloid fibrils were labelled with 10-nm gold particles to anti-A κ antiserum and the thick ones with 20-nm gold particles to anti- β 2-M antiserum (Fig. 5). This immunolabelling was always observed on the amyloid fibrils and no labelling was seen on nonfibrillar structures.

Immunoreaction with anti-human AA and human A λ antibodies was not seen in amyloid fibrils using immunogold electron microscopy. In sections from positive controls (AA, A κ , A λ , or A β 2M amyloidosis) gold particles with the respective antibodies labelled amyloid fibrils in each type.




Fig. 4a–c Immunogold electron microscopy at the nodular area of amyloid deposit. **a** Immunoreaction product (10-nm gold particles) to anti-A κ antiserum is located on thin amyloid fibrils. Single labelling procedure, $\times 56000$. **b** Immunoreaction product (20-nm gold particles) to anti- β_2 -microglobulin antiserum is seen on thick amyloid fibrils. Single labelling procedure, $\times 56000$. **c** A double labelling preparation demonstrates different sizes of gold particles on respective amyloid fibrils. Double labelling procedure, $\times 56\,000$

Discussion

The immunogold electron microscopic technique has recently been applied for the identification of the subcellular topographic localization of antigenic sites. In amyloidosis, several investigations have been conducted using this technique for the classification and identification of different amyloids using antibodies against amyloid proteins [6, 14]. In the present study, we used a double labelling method with a two-surface reaction in which each antibody bound to antigenic sites was detected by a particular size of colloidal gold probe. Colocalization of A κ and A β 2M amyloid fibrils has been clearly demonstrated in the same tissue in a patient with systemic amyloidosis: different-sized gold particles decorated different

amyloid fibrils (10-nm gold particles to anti-A κ antiserum on thin amyloid fibrils and 20-nm gold particles to anti- β 2-M antiserum on thick ones).

By light microscopic immunohistochemical methods, coincidental immunoreactivities for two or more amyloid proteins in a single patient with systemic amyloidosis have been reported by several investigators [3, 7, 11, 15, 24]. The coexistence of AA and A β 2M amyloidoses was most frequently demonstrated in various tissues and organs. There has been no reported case of the coexistence of AL and A β 2M amyloids. In most of the reported cases two different amyloids showed different distributions in different organs, or even in the same organ. To our knowledge, only three cases in which colocalization of two different amyloids (AA and A β 2M) has been demonstrated in the same tissue have been found in the literature [3, 7, 11]. In one of them, two morphologically different amyloid fibrils – curvilinear microfibrils characteristic of A β 2M fibrils and crossed straight microfibrils representing other types of amyloid fibrils – were also demonstrated by conventional electron microscopy [7].

In the present study the amyloid deposits reacted not only with anti-A κ and anti- β 2-M antisera but also with anti-A λ antiserum on light microscopic immunohisto-




Fig. 5 Immunogold electron microscopy in a diffuse area of amyloid deposit. Two cytochemically different amyloid fibrils, thin amyloid fibrils labelled with 10-nm gold particles to anti-Aκ antiserum and thick amyloid fibrils labelled with 20-nm gold particles to anti-β₂-microglobulin antiserum, are intermingled. Double labelling procedure, ×110000

chemistry. Immunostaining with AL antibodies in AA or Aβ₂M amyloidosis seems to result from nonspecific trapping of immunoglobulins within amyloid deposits [20]. However, it has been suggested that in immunogold electron microscopic preparations the relevant antigenicity for trapped plasma proteins is not preserved by the tissue processing or revealed by the etching procedure [6]. In our study, no labelling of gold particles was seen on the amyloid fibrils when anti-Aλ antiserum was applied as primary antibody. Therefore it is reasonable to assume that the immunoreactivity for Aλ in the present light microscopic immunohistochemical study was due to trapped immunoglobulin λ-light chain in amyloid deposits.

Aβ₂M amyloidosis affects mainly synovial membranes in patients undergoing chronic haemodialysis and causes osteoarthropathies [8]. Recently Aβ₂M amyloid deposits have been demonstrated in various organs other than the osteoarticular region [4] and Aβ₂M amyloidosis is generally accepted to be a systemic disease. Contro-

versy exists about the electron microscopic appearance of Aβ₂M amyloid. Initial reports demonstrated a peculiar type of fibril with a "curvilinear" appearance [5, 17, 19], but since these several ultrastructural reports have demonstrated β₂-M-derived amyloid fibrils with features common to all other chemical types of amyloid [21, 26]. These differences might be related to the fixation of affected tissues, staining of thin sections, or duration of the deposit. Using immunogold electron microscopy, we have studied several patients with Aβ₂M amyloidosis who were undergoing chronic haemodialysis, and the fibrils in all patients so far examined have had a peculiar curvilinear appearance and formed short bundles (unpublished data) similar to those seen in the present study. These findings indicate that Aβ₂M amyloid shows characteristic ultrastructural features in some circumstances, which distinguish it from other amyloidosis.

AL amyloidosis is one of the best known systemic forms and is often associated with multiple myeloma or related conditions. AL proteins consist of either the whole molecule or fragments of monoclonal immunoglobulin light chains. Fibrillogenesis of AL and AA amyloidosis involves the partial proteolytic cleavage of precursor proteins into fragments with a propensity for aggregating into anti-parallel β-pleated sheets [9]. However, Aβ₂M amyloid is composed of the entire sequence of the amyloid proteins (β₂-microglobulin), which strongly suggests the polymerization of intact β₂-M in tissues [10]. Linke et al. have reported that β₂-M fragmentation is common in amyloid deposits and suggested that limited proteolysis with lysine-specific protease(s) play s an important part in the pathogenesis of Aβ₂M amyloidosis [16].

Since it is uncertain whether Aκ and Aβ₂M amyloids in the present case are derived from whole proteins or fragments and what protease(s) effect(s) in cleavage of the precursor proteins, the underlying mechanism of fibrillogenesis of the amyloids remains unclear. However, predisposing amyloid deposits might be attributable to another amyloid deposition, because amyloid fibrils thereof are known to possess the activity of amyloid-enhancing factor [18].

Acknowledgements The authors wish to express their appreciation to Drs. Tatsuo Matsushita and Shinji Sawada (Kitano Hospital, Osaka) for providing the valuable specimens. This work was supported by a Research Grant for Scientific Diseases from the Ministry of Health and Welfare.

References

1. Bendayan M (1982) Double immunocytochemical labeling applying the protein A-gold technique. *J Histochem Cytochem* 30:81–85
2. Bendayan M, Zollinger M (1983) Ultrastructural localization of antigenic sites on osmium-fixed tissues applying the protein A-gold technique. *J Histochem Cytochem* 31:101–109
3. Borczuk A, Mannion C, Dickson D, Alt E (1995) Intestinal pseudo-obstruction and ischemia secondary to both β₂-microglobulin and serum A amyloid deposition. *Mod Pathol* 8:577–582

4. Campistol JM, Solé M, Muñoz-Gomez J, Lopez-Pedret J, Revert L (1990) Systemic involvement of dialysis-amyloidosis. *Am J Nephrol* 10:389–396
5. Casey TT, Stone WJ, DiRaimondo CR, Brantley BD, DiRaimondo CV, Gorevic PD, Page DL (1986) Tumoral amyloidosis of bone of beta₂-microglobulin origin in association with long-term hemodialysis: a new type of amyloid disease. *Hum Pathol* 17:731–738
6. Donini U, Casanova S, Zucchelli P, Linke RP (1989) Immuno-electron microscopic classification of amyloid in renal biopsies. *J Histochem Cytochem* 37:1101–1106
7. Fernandez-Alonso J, Rios-Camacho C, Valenzuela-Castaño A, Hernanz-Mediano W (1994) Mixed systemic amyloidosis in a patient receiving long term haemodialysis. *J Clin Pathol* 47:560–561
8. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Shmid K (1985) A new form of amyloid protein associated with chronic hemodialysis was identified as β₂-microglobulin. *Biochem Biophys Res Commun* 129:701–706
9. Glenner GG (1980) Amyloid deposits and amyloidosis. The β-fibrilloses. *N Engl J Med* 302:1283–1292, 1333–1343
10. Gorevic PD, Munoz PC, Casey TT, DiRaimondo CR, Stone WJ, Prelli FC, Rodrigues MM, Poulik MD, Frangione B (1986) Polymerization of intact β₂-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. *Proc Natl Acad Sci USA* 83:7908–7912
11. Hoshii Y, Takahashi M, Ishihara T, Uchino F (1994) Immunohistochemical classification of 140 autopsy cases with systemic amyloidosis. *Pathol Int* 44:352–358
12. Husby G, Araki S, Benditt EP, Benson MD, Cohen AS, Frangione B, Glenner GG, Natvig JB, Westermark P (1991) The 1990 guidelines for nomenclature and classification of amyloid and amyloidosis. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P (eds) *Amyloid and amyloidosis 1990*. Kluwer, Dordrecht Boston London, pp 7–11
13. Isersky C, Ein D, Page DL, Harada M, Glenner GG (1972) Immunochemical cross-reactions of human amyloid proteins with human immunoglobulin light polypeptide chains. *J Immunol* 108:486–493
14. Linke RP, Nathrath WBJ, Wilson PD (1983) Immuno-electron microscopic identification and classification of amyloid in tissue sections by the postembedding protein-A gold method. *Ultrastruct Pathol* 4:1–7
15. Linke RP, Kunert U, Lobeck H, Hampl H, Eulitz M (1988) Chemical analysis of beta₂-microglobulin derived amyloid in patients on long-term hemodialysis. In: Isobe T, Araki S, Uchino F, Kito S, Tsubura E (eds) *Amyloid and amyloidosis*. Plenum Press, New York, pp 611–616
16. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R, Eulitz M (1989) Lysine-specific cleavage of β₂-microglobulin in amyloid deposits associated with hemodialysis. *Kidney Int* 36:675–681
17. Morita T, Suzuki M, Kamimura A, Hirasawa Y (1985) Amyloidosis of a possible new type in patients receiving long-term hemodialysis. *Arch Pathol Lab Med* 109:1029–1032
18. Niewold T, Hol PR, van Andel ACJ, Lutz ETG, Gruys E (1987) Enhancement of amyloid induction by amyloid fibril fragments in hamster. *Lab Invest* 56:544–549
19. Nishi S, Ogino S, Maruyama Y, Honma N, Gejyo F, Morita T, Arakawa M (1990) Electron-microscopic and immunohistochemical study of beta-2-microglobulin-related amyloidosis. *Nephron* 56:357–363
20. Orfila C, Rakotoarivony J, Segonds A, Suc J-M (1983) Immunofluorescence study of “non-idiopathic” renal amyloidosis. *Hum Pathol* 14:362–367
21. Picken MM, Shen S (1994) β₂-Microglobulin amyloidosis: illustrative cases. *Ultrastruct Pathol* 18:133–136
22. Puchtler H, Sweat F, Levine M (1962) On the binding of Congo red by amyloid. *J Histochem Cytochem* 10:355–364
23. Shi Z-R, Itzkowitz SH, Kim YS (1988) A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. *J Histochem Cytochem* 36:317–322
24. Störkel S, Stürer A (1989) Kombinierte Amyloidose vom Typ AA und AB nach chronischer Hämodialyse. *Pathologe* 10:107–113
25. Tan SY, Pepys MB (1994) Amyloidosis. *Histopathology* 25:403–414
26. Turbat-Herrera EA (1994) β₂-Microglobulin and the kidney: an overview. *Ultrastruct Pathol* 18:99–103